small molecule

NEXLETOL

BEMPEDOIC ACID

Loss of exclusivityJune 2040latest FDA-listed patent expiry

CompanyEsperion Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	NEXLETOL
Active ingredient	BEMPEDOIC ACID
Strength	180MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
11760714	June 2040	product
11926584	June 2040	use U-3873
12404227	June 2040	substance
12398087	June 2040	substance, product
11613511	June 2040	substance
11744816	March 2036	use U-3883
7335799	December 2030	substance

Regulatory exclusivity

Code	Expires
I-943	March 2027
I-944	March 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Esperion Therapeutics